NCT03960437View on ClinicalTrials.gov

The Effect of Etelcalcetide on CKD-MBD

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

November 19, 2020

Study Completion Date

November 19, 2020

Conditions
Chronic Kidney Disease Mineral and Bone DisorderRenal OsteodystrophyVascular CalcificationHyperparathyroidism; Secondary, Renal
Interventions
DRUG

Etelcalcetide

Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
lead

Thomas Nickolas, MD MS

OTHER

NCT03960437 - The Effect of Etelcalcetide on CKD-MBD | Biotech Hunter | Biotech Hunter